FDA’s Pazdur: Accelerated Approval Is ‘Under Attack,' Supporters Can’t Afford To Remain Silent

 
• By Sarah Karlin-Smith
Reps. Diana DeGette, Fred Upton and Pazdur and Sharpless discuss Cures 2.0
Cures 2.0 Congressional sponsors discuss expedited approval pathways with FDA’s Pazdur and NCI’s Sharpless • Source: Friends of Cancer Research

More from United States

More from North America